NCT04047017View on ClinicalTrials.gov

Camrelizumab Combined With Apatinib for Recurrent Resistant GTN

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 8, 2019

Primary Completion Date

March 18, 2021

Study Completion Date

May 15, 2021

Conditions
Gestational Trophoblastic Disease
Interventions
DRUG

Apatinib

250mg, po, qd

DRUG

Camrelizumab

200mg, q2w

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT04047017 - Camrelizumab Combined With Apatinib for Recurrent Resistant GTN | Biotech Hunter | Biotech Hunter